Keylynk

Keylynk company information, Employees & Contact Information

Explore related pages

Related company profiles:

Keylynk Business Consulting Private Limited firm specializes in providing Business solutions, Specializes in sourcing profiles, helping Ideas meet best minds to support and in the optimization of business processes. Our in-depth knowledge of industry combined with our collaborative business approach makes us a key link to take the business forward - of any size, any sector, National, International With our clear and in-depth understanding of the concerns, challenges and realities of each industry, we support our clients to improve their business. Our business consulting and functional services cover the following aspects: Content Marketing Training/Upskilling/Workshop Talent Acquisition ITES Y V ( Why We) Passion A passionate team committed to drive positive change in the company and the lives of the people who work in it. Curious and creative, we work in all circumstances with pride, enthusiasm and dedication. Integrity We say what we do and we do what we say. Honesty, Reliability and Caring are building blocks of the relationship we build within our Organization, Clients & Partners Alliance Everyone can have good ideas and the plurality of points of view favors creativity. Believing that the whole is greater than the sum of its parts and, from this principle, we value teamwork and collaboration. Excellence We are passionate about excellence and we strive to meet the needs of our customers and anticipate their needs and ex

Company Details

Employees
65
Founded
-
Address
Bangalore, Karnataka 560011, In
Industry
Education Administration Programs
NAICS
Administration of Education Programs
HQ
Bangalore, Karnataka
Looking for a particular Keylynk employee's phone or email?

Keylynk Questions

News

The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC - ScienceDirect.com

The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC ScienceDirect.com

Keytruda/Lynparza link-up disappoints again | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Keytruda/Lynparza link-up disappoints again | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Merck gets rare win with Keytruda-Lynparza combo but role of Keytruda in ovarian cancer 'remains uncertain' - Fierce Pharma

Merck gets rare win with Keytruda-Lynparza combo but role of Keytruda in ovarian cancer 'remains uncertain' Fierce Pharma

Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival in Patients With Advanced... - Medical Dialogues

Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival in Patients With Advanced... Medical Dialogues

Phase 3 Trial of Pembrolizumab (Keytruda) Combo in Advanced Ovarian Cancer Raises Questions - Oncology News Central

Phase 3 Trial of Pembrolizumab (Keytruda) Combo in Advanced Ovarian Cancer Raises Questions Oncology News Central

Pembrolizumab/Olaparib Yields PFS Significance in Advanced Ovarian Cancer - CancerNetwork

Pembrolizumab/Olaparib Yields PFS Significance in Advanced Ovarian Cancer CancerNetwork

Keytruda, Lynparza break clinical losing streak with partial win in ovarian cancer - FirstWord Pharma

Keytruda, Lynparza break clinical losing streak with partial win in ovarian cancer FirstWord Pharma

Merck Halts Phase 3 Pembrolizumab/Olaparib Trial in NSCLC - Targeted Oncology

Merck Halts Phase 3 Pembrolizumab/Olaparib Trial in NSCLC Targeted Oncology

Merck shares positive phase 3 results for Keytruda/Lynparza regimen in ovarian cancer - PMLiVE

Merck shares positive phase 3 results for Keytruda/Lynparza regimen in ovarian cancer PMLiVE

Again, Keytruda and PARP fail to lynk | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Again, Keytruda and PARP fail to lynk | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Primary End Points Not Met With Pembrolizumab/Olaparib in NSCLC Trial - CancerNetwork

Primary End Points Not Met With Pembrolizumab/Olaparib in NSCLC Trial CancerNetwork

Tumor-Agnostic Trial Finds PARP Inhibitor and Anti-PD-L1 Combo Beneficial Across Cancer Types - Oncology News Central

Tumor-Agnostic Trial Finds PARP Inhibitor and Anti-PD-L1 Combo Beneficial Across Cancer Types Oncology News Central

Merck’s Lynparza-Keytruda combo sputters in 2nd lung cancer trial. Will an ADC pairing work instead? - Fierce Pharma

Merck’s Lynparza-Keytruda combo sputters in 2nd lung cancer trial. Will an ADC pairing work instead? Fierce Pharma

Phase 3 KEYLYNK-008 Trial of Pembrolizumab Plus Olaparib in Metastatic Squamous NSCLC to Stop for Futility - OncLive

Phase 3 KEYLYNK-008 Trial of Pembrolizumab Plus Olaparib in Metastatic Squamous NSCLC to Stop for Futility OncLive

Jemperli aims for ovarian white space | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Jemperli aims for ovarian white space | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

AACR: Detailed data spark glimmer of hope for Merck's Keytruda-Lynparza combo in lung cancer - Fierce Pharma

AACR: Detailed data spark glimmer of hope for Merck's Keytruda-Lynparza combo in lung cancer Fierce Pharma

Mirroring Merck's problem, GSK's Jemperli-Zejula study in ovarian cancer misses survival goal - Fierce Pharma

Mirroring Merck's problem, GSK's Jemperli-Zejula study in ovarian cancer misses survival goal Fierce Pharma

For Merck, Lynparza fails to improve on Keytruda in first-line lung cancer - Fierce Pharma

For Merck, Lynparza fails to improve on Keytruda in first-line lung cancer Fierce Pharma

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant